Freedom Broker cuts Alnylam stock price target on execution risks

Freedom Broker cut Alnylam’s price target to $350 from $410 but maintained a Buy rating; the article says shares were at $170 after falling 22% in the past week. The analyst cited AMVUTTRA execution and access risks, potential pricing pressure, and modeled 22% growth in 2027, while noting structural Sanofi royalty costs and one-time items that flattered results. Other firms also lowered targets, ranging from $225 to $329, with ratings varying from Hold to Buy.

Analysis

ALNY’s key risk is now earnings quality, not whether AMVUTTRA has demand: if incremental prescribers produce fewer patients while the Sanofi royalty burden rises with volume, sales growth can translate into weaker-than-expected gross-profit growth. That creates downside to both earnings estimates and the premium investors may assign to the franchise. The reported EBIT beat is a weak counterweight if it depended on expense timing.

Near term, the selloff and repeated target cuts raise the risk that a crowded negative read-through is already reflected in the share price; initiating an unhedged short here has poor asymmetry without fresh evidence of deteriorating patient additions. Over the next 1–3 months, focus on patient starts, prescriber conversion, gross margin/royalty progression, and management’s 2027 outlook. The 340B issue is a specific Q1 2027 catalyst, while nucresiran is a longer-dated, unproven offset—not a near-term valuation floor. A stronger conversion trend or stable gross margin would falsify the execution-bear case. Sanofi may receive incremental royalty benefit as volume grows, but the article provides no basis to size that against its broader business; it is not a standalone SNY catalyst.

Key Decisions for Investors

• Keep ALNY underweight rather than chase the decline with an outright short. Consider a defined-risk put spread only after a rebound or ahead of a catalyst, with premium at risk capped; avoid paying for downside protection if implied volatility is already elevated.
• Use the next company update to test the thesis: downgrade further if patient additions or prescriber conversion weaken and gross margin confirms rising royalty drag; cover/reassess if conversion improves and gross margin holds despite higher volume.
• Treat Q1 2027 340B exposure as a dated risk to estimates, not a certainty. Verify management’s quantified impact and any offset from access or patient growth before adding exposure.
• Do not use SNY as a hedge or paired long without evidence that ALNY royalties are material to Sanofi’s earnings; the supplied information does not establish that sensitivity.